TY - JOUR
T1 - Preventive Effects of Non-sedating and Sedating Histamine H₁ Receptor Antagonists Premedication for Subcutaneous Daratumumab-Associated Infusion-Related Reactions
T2 - A Prospective Observational Study
AU - Yakumaru-Suzukawa, Mayu
AU - Aomori, Tohru
AU - Suzuki, Norifumi
AU - Ohata, Koichi
AU - Abumiya, Maiko
AU - Fujita, Yukiyoshi
AU - Yoshizawa, Tomoe
AU - Matsumoto, Kaori
AU - Kudo, Akira
AU - Suehiro, Naoya
AU - Hishida-Sadaka, Shiori
AU - Igarashi, Haruka
AU - Inoue, Chinami
AU - Yamazaki, Tomoko
AU - Wakatsuki, Junichiro
AU - Sakurai, Hiroomi
AU - Banno-Matsuoka, Serika
AU - Fukushi, Yayoi
AU - Iihara, Hirotoshi
AU - Kikuchi, Masafumi
AU - Kawazoe, Hitoshi
AU - Ohtani, Hisakazu
N1 - Publisher Copyright:
© 2026 The Author(s). This is an open access article distributed under the terms of Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/). Published by The Pharmaceutical Society of Japan.
PY - 2026
Y1 - 2026
N2 - The optimal choice between sedating histamine H₁ antagonists (sAHs) and non-sedating histamine H₁ antagonists (nsAHs) for preventing infusion-related reactions (IRRs) during daratumumab subcutaneous (DARA-SC) therapy remains unclear. Here, we aimed to compare the efficacy and safety of nsAH and sAH as premedication for DARA-SC therapy. Patients with multiple myeloma or light-chain amyloidosis who received DARA-SC therapy at eight hospitals were enrolled in this prospective, multicenter, observational study. Patients were categorized into nsAH and sAH groups based on their premedication. IRRs and drowsiness were assessed using patient-reported questionnaires, including the Stanford Sleepiness Scale (SSS) and the Japanese Epworth Sleepiness Scale (JESS), at baseline, post-administration (Q2), and before bedtime (Q3). Overall, 104 patients (nsAH, n = 49; sAH, n = 55) were analyzed. No significant differences were observed in the IRR incidence between the nsAH and sAH groups at Q2 (8.2 vs. 9.1%) or Q3 (13 vs. 17%). Conversely, the incidence of new-onset drowsiness at Q2 was significantly lower in the nsAH group (13%) than in the sAH group (32%, p < 0.05). Additionally, the increase in SSS from baseline to Q2 was significantly lower in the nsAH group than in the sAH group (p < 0.05). No significant differences were observed in JESS scores. Thus, nsAH was associated with reduced early post-administration drowsiness and there were no statistically significant differences in IRR preventive effects compared to that for sAH, suggesting that nsAH may reduce sedation without a significant increase in the incidence of IRRs; however, these hypothesis-generating findings warrant verification through future prospective comparative trials.
AB - The optimal choice between sedating histamine H₁ antagonists (sAHs) and non-sedating histamine H₁ antagonists (nsAHs) for preventing infusion-related reactions (IRRs) during daratumumab subcutaneous (DARA-SC) therapy remains unclear. Here, we aimed to compare the efficacy and safety of nsAH and sAH as premedication for DARA-SC therapy. Patients with multiple myeloma or light-chain amyloidosis who received DARA-SC therapy at eight hospitals were enrolled in this prospective, multicenter, observational study. Patients were categorized into nsAH and sAH groups based on their premedication. IRRs and drowsiness were assessed using patient-reported questionnaires, including the Stanford Sleepiness Scale (SSS) and the Japanese Epworth Sleepiness Scale (JESS), at baseline, post-administration (Q2), and before bedtime (Q3). Overall, 104 patients (nsAH, n = 49; sAH, n = 55) were analyzed. No significant differences were observed in the IRR incidence between the nsAH and sAH groups at Q2 (8.2 vs. 9.1%) or Q3 (13 vs. 17%). Conversely, the incidence of new-onset drowsiness at Q2 was significantly lower in the nsAH group (13%) than in the sAH group (32%, p < 0.05). Additionally, the increase in SSS from baseline to Q2 was significantly lower in the nsAH group than in the sAH group (p < 0.05). No significant differences were observed in JESS scores. Thus, nsAH was associated with reduced early post-administration drowsiness and there were no statistically significant differences in IRR preventive effects compared to that for sAH, suggesting that nsAH may reduce sedation without a significant increase in the incidence of IRRs; however, these hypothesis-generating findings warrant verification through future prospective comparative trials.
KW - drowsiness
KW - infusion-related reaction
KW - non-sedating histamine H₁ antagonist
KW - sedating histamine H₁ antagonist
KW - subcutaneous daratumumab
UR - https://www.scopus.com/pages/publications/105045507573
UR - https://www.scopus.com/pages/publications/105045507573#tab=citedBy
U2 - 10.1248/bpb.b26-00011
DO - 10.1248/bpb.b26-00011
M3 - Article
C2 - 42528221
AN - SCOPUS:105045507573
SN - 0918-6158
VL - 49
SP - 1153
EP - 1160
JO - Biological and Pharmaceutical Bulletin
JF - Biological and Pharmaceutical Bulletin
IS - 7
ER -